Eli Lilly and Co. stock: Bernstein lifts USD 1,450 target, slightly higher pre-market
Published on 10/27/2026 at 07:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst action and earnings date
- Bernstein raised its Eli Lilly price target to USD 1,450 on October 26, 2026.
- Eli Lilly's Q3 2026 earnings call is scheduled for October 29, 2026.
- Eli Lilly and Co. stock trades pre-market at EUR 1,148.20 at 7:36 a.m. CET at Lang & Schwarz on October 27, 2026, plus 0.38 percent above the Xetra close of October 26, 2026.
On October 26, 2026, Bernstein raised its price target for Eli Lilly to USD 1,450 from USD 1,385 and maintained an Outperform rating, as reported by Markets Insider. Eli Lilly and Co. stock trades pre-market at EUR 1,148.20 at 7:36 a.m. CET at Lang & Schwarz on October 27, 2026, plus 0.38 percent above the Xetra close of October 26, 2026 (EUR 1,143.80).
Analyst target ahead of earnings
The Bernstein estimate puts third-quarter revenue at USD 22.62 billion, compared with Bloomberg median consensus of USD 22.45 billion, according to the Markets Insider report. The report also cited adjusted EPS of USD 5.48, including USD 4.20 billion of acquired in-process research and development. Bernstein analyst Courtney Breen raised the target from USD 1,385 while retaining the Outperform rating.
Ahead of the Xetra open
The pre-market indication is EUR 4.40 above the Xetra close of October 26, 2026. The further course from the Xetra open at 9:00 a.m. CET is shown by the continuously updated real-time quote of Eli Lilly stock.
Business and the day ahead
Eli Lilly researches, develops and commercializes human medicines worldwide, earning revenue from its pharmaceutical products. The company's Q3 2026 earnings call is scheduled for October 29, 2026, at 10:00 a.m. EDT, according to Eli Lilly and Company. Market context: Market report S&P 500.
